Sudler & Hennessey appoints Co-CEOs

Share this article:

Sudler & Hennessey (S&H) has announced the appointment of co-CEOs – Rob Rogers and Louisa Holland – to head all operations in the Americas. The announcement was made in a statement on June 30. 

Rogers was the president of S&H's Asia Pacific operations from 2003 to 2006, before returning to the US as chief creative officer for North America. He will join Louisa Holland, previously the president of US operations, in the newly created co-CEO position.

“Rob and Louisa bring different skill sets which complement one another,” said Jed Beitler, chairman and worldwide CEO, adding that Rogers has international and promotional experience, while Holland is well versed in the domestic market and medical education, for example. “[The new appointments] increase our peripheral vision – the industry is no longer siloed in terms of disciplines, and the combined diversity and talent of Rob and Louisa insures that everything we do for our clients is in keeping with the evolving marketplace and changing world,” said Beitler.

Rogers and Holland are based out of S&H's New York City office. According to Beitler, the decision to establish co-CEOs reflects a philosophy of evolution at S&H, and a consolidation of geographical operations. “[Rogers and Holland]” are in charge of everything from the Hudson Bay down to Tierra del Fuego,” said Beitler. S&H is a subsidiary of Young & Rubicam, which was acquired by the London-based WPP Group in 2000.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...